CMS Proposes Removing TAVR Coverage Barrier, Bolstering Edwards' Growth Outlook

What happened

On Monday, CMS proposed removing the coverage with evidence development (CED) requirement for TAVR in symptomatic severe aortic stenosis, a move that would eliminate a key administrative hurdle and potentially expand patient access. For Edwards Lifesciences, the dominant TAVR player with the only approved indication for asymptomatic severe AS, this could accelerate procedure volume growth beyond the 6-8% base case assumed in our recent analysis. The DeepValue report already accounted for guideline tailwinds, but a formal CMS policy change would directly reduce reimbursement uncertainty and could push TAVR growth toward the 9-10% bull case, especially as Edwards leverages its first-mover advantage in earlier-stage patients. However, the proposal remains subject to public comment and finalization, and prior CMS initiatives have faced delays or modifications. While the news is unequivocally positive, the stock's current valuation near $84 (~28-29x 2026 EPS) already embeds significant optimism, limiting upside unless execution exceeds already-elevated expectations.

Implication

If finalized, removal of CED for TAVR would structurally lower access barriers, reinforcing Edwards' revenue durability and supporting the bull-case scenario of sustained 9-10% TAVR growth. This strengthens the investment thesis over a 12-18 month horizon, but given the current price, the risk-reward remains balanced; maintain a wait-and-see stance until a better entry or confirmation of execution on TMTT and asymptomatic TAVR adoption.

Thesis delta

The proposed removal of CED for TAVR directly reduces reimbursement risk, increasing the probability of the bull case (25% → ~35%) where TAVR sustains 9-10% growth. However, the base case remains intact, and the stock already trades near the bull case's implied value, so the call shifts to slightly more constructive but still neutral – we prefer to wait for a more attractive entry below $75 or confirmation of TMTT upside.